ScholarIQanswers from OpenAlex & ORCID
Pieter Sonneveld
ResearcherPublications, citations & collaboration network
Pieter Sonneveld is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Pieter Sonneveld have?
ScholarIQindexed works
Pieter Sonneveld has 1,254 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Pieter Sonneveld have?
ScholarIQcitation count
Pieter Sonneveld has 78,087 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Pieter Sonneveld?
ScholarIQh-index
Pieter Sonneveld has an h-index of 127 in OpenAlex.
What is the i10-index of Pieter Sonneveld?
ScholarIQi10-index
Pieter Sonneveld has an i10-index of 591 in OpenAlex.
What is the ORCID of Pieter Sonneveld?
ScholarIQorcid
The ORCID for Pieter Sonneveld is on the source record.
What is the OpenAlex record for Pieter Sonneveld?
ScholarIQopenalex
The OpenAlex for Pieter Sonneveld is on the source record.
What are the most-cited papers on Pieter Sonneveld?
ScholarIQmost cited works
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C. Anderson, Brian G.M. Durie, Ola Landgren, Philippe Moreau, Nikhil C. Munshi, Sagar Lonial, Joan Bladé, María‐Victoria Mateos, Meletios Α. Dimopoulos, Efstathios Kastritis, Mario Boccadoro, Robert Z. Orlowski, Hartmut Goldschmidt, Andrew Spencer, Jian Hou, Wee Joo Chng, Saad Z. Usmani, Elena Zamagni, Kazuyuki Shimizu, Sundar Jagannath, Hans Erik Johnsen, Evangelos Terpos, Tony Reiman, Robert A. Kyle, Pieter Sonneveld, Paul G. Richardson, Philip L. McCarthy, Heinz Ludwig, Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Laurent Garderet, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Pascal Lenain, Margaret Macro, Claire Mathiot, Frédérique Orsini‐Piocelle, Aurore Perrot, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Juul Vangsted, Hermann Einsele, Andrew Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
María‐Victoria Mateos, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Mohamad Mohty, Michèle Cavo, Ravi Vij, Joanne Lindsey-Hill, Dominik Dytfeld, Emanuele Angelucci, Aurore Perrot, Reuben Benjamin, Niels W.C.J. van de Donk, Enrique M. Ocio, Christof Scheid, Francesca Gay, Wilfried Roeloffzen, Paula Rodríguez‐Otero, Annemiek Broijl, Anna Potamianou, Caline Sakabedoyan, Maria Semerjian, Sofia Keim, Vadim Strulev, Jordan M. Schecter, Martin Vogel, Robert Wapenaar, Tonia Nesheiwat, Jesús F. San Miguel, Pieter Sonneveld, Hermann Einsele, Philippe Moreau
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Véronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld